Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.59 |
| ▸ | FPR2 | P25090 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MYLK | Q15746 | 2/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 7/20 | 0.58 |
| ▸ | THPO | P40225 | 3/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16002831 | 0.89 | MEN1 (0.56) | CYP3A4CYP1A2CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL11821856 | 0.88 | NSD2 (0.52) | CYP3A4CYP1A2CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL11807892 | 0.83 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL2372746 | 0.81 | PTGES2 (0.54) | TSHR | |
| SCHEMBL15177884 | 0.81 | CYP3A4 (0.69) | CYP3A4CYP1A2CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL16000104 | 0.81 | CYP3A4 (0.55) | CYP3A4CYP1A2CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL2371935 | 0.80 | GAA (0.58) | CYP1A2HSD17B10TSHRALDH1A1EDNRA | |
| SCHEMBL20977444 | 0.79 | CYP1A2 (0.50) | CYP1A2TSHRALDH1A1LMNACYP2A6 | |
| SCHEMBL14030904 | 0.79 | CYP1A2 (0.54) | CYP3A4CYP1A2CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL3683320 | 0.78 | CYP3A4 (0.79) | CYP3A4CYP1A2CYP2C19CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-9199959-B2 | HIV replication inhibitor | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| WO-2011022638-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| US-7026475-B2 | Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-04-11 | — | — | US | disclosed |
| US-20040122003-A1 | Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-06-24 | — | — | US | disclosed |
| US-20040116412-A1 | Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-06-17 | — | — | US | disclosed |
| EP-1404340-A1 | NAPHTOTHIAZINE POSITIVE ALLOSTERIC AMPA RECEPTOR MODULATORS (PAARM) | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030100552-A1 | Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-05-29 | — | — | US | disclosed |
| WO-2002100411-A1 | NAPHTOTHIAZINE POSITIVE ALLOSTERIC AMPA RECEPTOR MODULATORS (PAARM) | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100552-A1 | Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions | GRM1, GRM2, GRIN1 | CYP3A4 1607/4885CYP1A2 2808/4885CYP2C19 1620/4885 |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | CYP3A4 3939/4885CYP1A2 3263/4885CYP2C19 3838/4885 |
| US-20040122003-A1 | Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions | GRM1, GRM2, GRIN1 | CYP3A4 1607/4885CYP1A2 2808/4885CYP2C19 1620/4885 |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SSU72, RTF2, ZC3HAV1 | CYP3A4 899/4885CYP1A2 1126/4885CYP2C19 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.